Table 1.
Potential clinical application of novel viral biomarkers in chronic hepatitis B infection.
| Viral Marker | The Possible Predictive Value | References |
|---|---|---|
| HBV RNA | NAs treatment response | [39,40,41] |
| NAs cessation | [36,42,43,44] | |
| Peg-IFNα treatment response | [39,43,46,47] | |
| Functional cure of chronic hepatitis B | [50] | |
| HBV-induced HCC | [52] | |
| Intrahepatic HBV cccDNA | [53,54] | |
| HBcrAg | NAs treatment response | [55] |
| Peg-IFNα treatment response | [56,57] | |
| HBeAg/HBsAg spontaneous seroconversion | [58,59,60,61,62] | |
| HBV reactivation due to immunosuppressive drug treatments. | [63] | |
| HBV-induced HCC | [64,65,66,67] | |
| Intrahepatic HBV cccDNA | [68,69] | |
| Anti-HBs | HBV reactivation due to immunosuppressive drug treatments | [70,71,72,73,74,75] |
| Anti-HBc | HBV reactivation due to immunosuppressive drug treatments | [75,76] |
| HBV occult infection | [77] |
HBcrAg—hepatitis B core-related antygen; anti-HBs—hepatitis B surface antibody; anti-HBc—hepatitis B core antibody.